A minority of people acquire HCV via alternate modes of transmission. Many of these individuals were born overseas and may have acquired the infection via:1

  • Unsterile vaccinations
  • Medical procedures
  • Injection treatment
  • Blood product transfusion from unscreened donors
  • Acupuncture
  • Endoscopy
  • Cultural practices such as public shaving or cupping

HCV initiatives in Australia

Unrestricted access to direct-acting antiviral (DAA) therapy and a diverse range of HCV models of care – including broad prescribing involvement and high coverage of harm reduction strategies for people who inject drugs (PWID) – have had a positive impact on HCV prevalence. Between 2015 and 2016, Australia witnessed a 12% fall in the prevalence of HCV – from 45% to 33% –  among 2,500 PWID included in the annual Australian Needle and Syringe Programme Survey.2

A combination of micro and macro elimination projects in Australia have demonstrated that universal access to DAAs, combined with expanded screening programmes, can increase uptake of treatment and reduced the prevalence of HCV, thereby paving the way for its elimination.3–6

Gilead is proud to support elimination efforts in marginalised populations. Gilead is working with healthcare professionals to prevent HCV among PWID and those in prisons through screening support and universal access to DAAs.2–4,7

Together we’re supporting elimination in Australia to help make HCV history.2–4,7

DAA, direct-acting antiviral; HCV, hepatitis C virus; PWID, people who inject drugs


While this information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact the accuracy of the information.

This page will be updated regularly.

Geographic populations


The TraP C elimination project in Iceland

Resource-limited settings


Details of elimination efforts in the Arkhangai Province, Mongolia

Eliminate HCV

Journey to elimination


An overview of the global ambition to eliminate viral hepatitis


  1. Holmes, J. Hepatitis C: An update. Available at: https://www.racgp.org.au/download/Documents/AFP/2013/July/201307holmes.pdf (accessed March 2019).
  2. Dore GJ and Hajarizadeh B. Elimination of Hepatitis C Virus in Australia: Laying the Foundation. Infect Dis Clin N Am 2018;32:269–279. 
  3. Sajed N, et al. Support of Global Efforts Toward Elimination of Hepatitis C Virus. Poster #28 presented at the International Viral Hepatitis Elimination Meeting (IVHEM 2017), Amsterdam, The Netherlands. Available at: www.gilead.com/-/media/files/pdfs/other/hcv%20infographic.pdf?la=en (accessed March 2019).
  4. Hajarizadeh B, et al. Poster THU-134. Presented at the International Liver Congress 2018, Paris, France.
  5. University of New South Wales, Kirby Institute. Press release: Control and Elimination within Australia of Hepatitis C from people living with HIV (CEASE), 2018. Available at: https://kirby.unsw.edu.au/project/control-and-elimination-within-australia-hepatitis-c-people-living-hiv-cease (accessed March 2019).
  6. Martinello M, et al. Poster THU-404. Presented at the International Liver Congress 2018, Paris, France.
  7. Kwon JA, et al. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. J Viral Hepat 2018. [Epub ahead of print]. 

LID/IHQ/18-12//1048h(1) Date of preparation August 2019